These trials completed more than 12 months ago and should have reported results.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
|Status||Trial ID||Title||Completion date||Category|
|Listed as ongoing, but also has a completion date||2017-004227-75||A Single Arm Open-Label Study to Evaluate the Therapeutic Effects and Safety of a 6-Week Treatment Regimen of ALK4290 in Patients with Newly Diagnosed Wet Age-Related Macular Degeneration (wAMD).||2018-11-21||bad-data|
|Listed as ongoing, but also has a completion date||2017-004228-31||A Single Arm Open-Label Study to Evaluate the Therapeutic Effects and Safety of a 6-Week Treatment Regimen of ALK4290 in Patients with Refractory Wet Age-Related Macular Degeneration (wAMD)||2018-11-29||bad-data|
|Ongoing||2019-001059-37||Double-Blind, Randomized, Placebo-Controlled Trial of AKST4290 for Adjunctive Treatment of Mild to Moderate Bullous Pemphigoid||not-yet-due|
|Ongoing||2019-001657-42||A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of AKST4290 in Subjects with Parkinson's Disease on Stable Dopaminergic Treatment||not-yet-due|
|Ongoing||2019-002738-36||A Double-Masked, Placebo-Controlled, Dose Ranging Study to Evaluate the Efficacy of Oral AKST4290 with Loading Doses of Aflibercept in Patients with Newly Diagnosed Neovascular Age-Related Macular Deg...||not-yet-due|
|Completed, report not yet due||2019-002821-31||The Effect of AKST4290 on Choroidal Blood Flow in Patients with Neovascular Age-Related Macular Degeneration||2020-04-27||not-yet-due|